However, because CRP is inherently elevated in patients with malignancy and the use of hormones can have an impact on its measurement, it is necessary to pay attention to whether the reduction in CRP correlates with improvements in other factors when assessing the recovery of patients with irAEs. The gene discussed is CRP; the disease is cancer.